Melanocortin receptor antagonists and modulations of melanocortin receptor activity
US6228840A · kind A · utility
16Cited by
7References
9Claims
0Family size
Inventors
Key dates
| Filing date | Feb 27, 1998 |
| Grant date | May 8, 2001 |
| Priority date | — |
| Expiry date | Feb 27, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The clinical outcome of disseminated melanoma is grim. Small molecular weight antagonists (preferably about seven amino acid residues) specific for MCR on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clinical significance. A particularly preferred antagonist is p-anisoyl-[D-Arg.sup.6,9, D-Lys.sup.11, D-Leu.sup.12 ] dynorphin A(6-12)-NH.sub.2, which is an excellent antagonist of the MCR-1 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.